Published in

Future Medicine, Pharmacogenomics, 8(18), p. 755-756, 2017

DOI: 10.2217/pgs-2017-0065

Future Medicine, Pharmacogenomics, 18(17), p. 1967-1969, 2016

DOI: 10.2217/pgs-2016-0162

Links

Tools

Export citation

Search in Google Scholar

ShouldCYP2D6be genotyped when treating with tamoxifen?

Journal article published in 2016 by Marzia Del Re ORCID, Eleonora Rofi, Valentina Citi, Leonardo Fidilio, Romano Danesi
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Letter in regards to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 17(18), 1967–1969 (2016). In response to: Damkier P. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients. Pharmacogenomics 18(8), XXX (2017).